Acadia Pharmaceuticals (ACAD) Short-term Investments (2010 - 2026)

Acadia Pharmaceuticals' Short-term Investments history runs 17 years deep, the most recent figure standing at $569.2 million for Q1 2026.

• On a quarterly basis, Short-term Investments rose 22.71% year-over-year to $569.2 million in Q1 2026; TTM through Mar 2026 was $569.2 million, a 22.71% increase from a year earlier, with the FY2025 full-year figure at $642.0 million, up 47.11% from the prior year.
• Short-term Investments declined to $569.2 million in Q1 2026 per ACAD's latest filing, from $642.0 million in the prior quarter.
• Across five years, Short-term Investments topped out at $642.0 million in Q4 2025 and bottomed at $112.0 million in Q1 2023.
• The 5-year median for Short-term Investments is $302.0 million (2022), against an average of $365.1 million.
• Across the five-year window, Short-term Investments plunged 53.55% in 2023 and surged 137.35% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $302.0 million in 2022, then decreased by 17.14% to $250.2 million in 2023, then jumped by 74.42% to $436.4 million in 2024, then soared by 47.11% to $642.0 million in 2025, then dropped by 11.33% to $569.2 million in 2026.
• Per Business Quant, the three latest ACAD Short-term Investments figures stand at $569.2 million (Q1 2026), $642.0 million (Q4 2025), and $589.0 million (Q3 2025).